A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Genentech, Inc.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT01375842
First received: June 16, 2011
Last updated: January 14, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2019
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):